维普期刊资源整合服务平台（V6.5）

55篇 您的检索式：作者名="Amado RG"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Wild - type KRAS is required for panitumumab efficacy in patients with meta- static colorectal cancer显示文摘	Amado RG Wolf M Peeters M	2008	J Clin 0ncol2008，26，：	1
2	Wild - type KRAS is required for panitumumab effcacy in patients with metastatic colorectal cancer 显示文摘	Amado RG Wolf M Peeters M	2008	J Clin Oncol2008，26，：	1
3	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer 显示文摘	Amado RG Wolf M Peeters M	2008	J Clin Oncol2008，26，10：	1
4	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer 显示文摘	Amado RG Wolf M Peeter M	2008	J Clin Oncol2008，26，：	1
5	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer显示文摘	Amado RG Wolf M Peeters M	2008	J Clin Oncol2008，26，10：	1
6	Wild-type KRAS isrequired for panitumumab efficacy in patients withmetastatic colorectal cancer显示文摘	Amado RG Wolf M Peeters M	2008	J Clin Oncol2008，26，10：	1
7	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer显示文摘	Amado RG Wolf M Peeters M	2008	J Clin Oncol2008，26，10：	1
8	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer 显示文摘	Amado RG Wolf M Peeters M	2008	J Clin Oncol2008，26，10：	1
9	Lentiviral vectors-the promise of gene therapy within reach?显示文摘	Amado RG Chen IS	1999	Science1999，285，5428：	1
10	Wild-type KRAS is re- quired for panitumumab efficacy in patients with metastasis color- ectal cancer显示文摘	Amado RG Wolf M Peeters M	2008	J Clin Oncol2008，26，10：	1
11	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer显示文摘	Amado RG Wolf M Peeters M	2008	J Clin Oneol2008，26，10：	1
12	Wild-type KRAS is required for panitunumab efficacy in patients with metastatic colorectal cancer显示文摘	Amado RG Wolf M Peeters M	2008	J Clin Oncol2008，26，10：	1
13	From XenoMouse first fully ihuman antibody product from transgenic mice 显示文摘	Jakobovits A Amado RG Yang technology to panitumumab the X	2007	Nat Biotechnol2007，25，10：	1
14	Effects of Megakaryocyte Growth and Development Factor on Survival and Retroviral Transduction of T Lymphoid Progenitor Cells显示文摘	AMADO RG SYMONDS G JAMIESON BD	1998	Hum Gene Ther1998，9，2：	1
15	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic coloreetal cancer显示文摘	Amado RG Wolf M Peeters M	2008	J Clin Oncol2008，26，10：	1
16	Wild-type K-RAS is required for panitumumab efficacy in patients with metastatic eolorectal cancer显示文摘	Amado RG Wolf M Peeters M	2008	Clin Oncol2008，26，10：	1
17	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer显示文摘	Amado RG Wolf M Peeters M	2008	J Clin Oncol2008，26，10：	1
18	Wild-type KRAS is required for panitunumab efficacy in patients with metastatic colorectal cancer显示文摘	Amado RG Wolf M Peeters M	2008	J Clin Oncol2008，26，10：	1
19	Wild-type K-RAS is required for panitumumab efficacy in patients with metastatic colorectal cancer显示文摘	Amado RG Wolf M Peeters M		0，，10：	1
20	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic celorectal cancer显示文摘	Amado RG Wolf M Peeters M	2008	J Clin Oncol2008，26，10：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示